T cell tolerance and activation to a transgene-encoded tumor antigen

Antony Antoniou, David McCormick, Diane Scott, Helen Yeoman, Phillip Chandler, Andrew Mellor, Julian Dyson

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Much has been learned in recent years concerning the nature of tumor antigens recognized by T cells. To apply this knowledge clinically, the nature of the host response to individual and multiple tumor antigens has to be characterized. This will help to define the efficacy of immune surveillance and the immune status of the host following exposure to tumor antigens expressed on pre-neoplastic tissue. To approach these questions, we have developed a transgenic mouse which expresses the tumor-specific antigen P91A. The single amino acid substitution in P91A results in the expression of a new MHC class I (H-2L(d))-binding peptide. In transgenic tissue, the H-2L(d)/P91A complex is expressed in isolation from other tumor-associated antigens, allowing definition of the immune response to a single defined tumor antigen, a situation closely analogous to events during tumorigenesis. We show that CD8+ T cell immune surveillance of P91A is ineffective without the introduction of a helper determinant operating through stimulation of CD4+ T cells. Recognition of the isolated P91A tumor antigen on normal tissue by CD8+ T cells is a tolerogenic process. Induction of T cell tolerance suggests tumor antigen-T cell interactions occurring during tumorigenesis may elicit T cell tolerance and hence confound some immunotherapeutic approaches.

Original languageEnglish (US)
Pages (from-to)1094-1102
Number of pages9
JournalEuropean Journal of Immunology
Volume26
Issue number5
DOIs
StatePublished - May 1 1996

Fingerprint

Neoplasm Antigens
Transgenes
T-Lymphocytes
Carcinogenesis
Amino Acid Substitution
Cell Communication
Transgenic Mice
Peptides

Keywords

  • H-Y
  • Tolerance
  • Transgene
  • Tumor antigen

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Antoniou, A., McCormick, D., Scott, D., Yeoman, H., Chandler, P., Mellor, A., & Dyson, J. (1996). T cell tolerance and activation to a transgene-encoded tumor antigen. European Journal of Immunology, 26(5), 1094-1102. https://doi.org/10.1002/eji.1830260521

T cell tolerance and activation to a transgene-encoded tumor antigen. / Antoniou, Antony; McCormick, David; Scott, Diane; Yeoman, Helen; Chandler, Phillip; Mellor, Andrew; Dyson, Julian.

In: European Journal of Immunology, Vol. 26, No. 5, 01.05.1996, p. 1094-1102.

Research output: Contribution to journalArticle

Antoniou, A, McCormick, D, Scott, D, Yeoman, H, Chandler, P, Mellor, A & Dyson, J 1996, 'T cell tolerance and activation to a transgene-encoded tumor antigen', European Journal of Immunology, vol. 26, no. 5, pp. 1094-1102. https://doi.org/10.1002/eji.1830260521
Antoniou A, McCormick D, Scott D, Yeoman H, Chandler P, Mellor A et al. T cell tolerance and activation to a transgene-encoded tumor antigen. European Journal of Immunology. 1996 May 1;26(5):1094-1102. https://doi.org/10.1002/eji.1830260521
Antoniou, Antony ; McCormick, David ; Scott, Diane ; Yeoman, Helen ; Chandler, Phillip ; Mellor, Andrew ; Dyson, Julian. / T cell tolerance and activation to a transgene-encoded tumor antigen. In: European Journal of Immunology. 1996 ; Vol. 26, No. 5. pp. 1094-1102.
@article{59d3aca30fab48d5aee868b625548522,
title = "T cell tolerance and activation to a transgene-encoded tumor antigen",
abstract = "Much has been learned in recent years concerning the nature of tumor antigens recognized by T cells. To apply this knowledge clinically, the nature of the host response to individual and multiple tumor antigens has to be characterized. This will help to define the efficacy of immune surveillance and the immune status of the host following exposure to tumor antigens expressed on pre-neoplastic tissue. To approach these questions, we have developed a transgenic mouse which expresses the tumor-specific antigen P91A. The single amino acid substitution in P91A results in the expression of a new MHC class I (H-2L(d))-binding peptide. In transgenic tissue, the H-2L(d)/P91A complex is expressed in isolation from other tumor-associated antigens, allowing definition of the immune response to a single defined tumor antigen, a situation closely analogous to events during tumorigenesis. We show that CD8+ T cell immune surveillance of P91A is ineffective without the introduction of a helper determinant operating through stimulation of CD4+ T cells. Recognition of the isolated P91A tumor antigen on normal tissue by CD8+ T cells is a tolerogenic process. Induction of T cell tolerance suggests tumor antigen-T cell interactions occurring during tumorigenesis may elicit T cell tolerance and hence confound some immunotherapeutic approaches.",
keywords = "H-Y, Tolerance, Transgene, Tumor antigen",
author = "Antony Antoniou and David McCormick and Diane Scott and Helen Yeoman and Phillip Chandler and Andrew Mellor and Julian Dyson",
year = "1996",
month = "5",
day = "1",
doi = "10.1002/eji.1830260521",
language = "English (US)",
volume = "26",
pages = "1094--1102",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - T cell tolerance and activation to a transgene-encoded tumor antigen

AU - Antoniou, Antony

AU - McCormick, David

AU - Scott, Diane

AU - Yeoman, Helen

AU - Chandler, Phillip

AU - Mellor, Andrew

AU - Dyson, Julian

PY - 1996/5/1

Y1 - 1996/5/1

N2 - Much has been learned in recent years concerning the nature of tumor antigens recognized by T cells. To apply this knowledge clinically, the nature of the host response to individual and multiple tumor antigens has to be characterized. This will help to define the efficacy of immune surveillance and the immune status of the host following exposure to tumor antigens expressed on pre-neoplastic tissue. To approach these questions, we have developed a transgenic mouse which expresses the tumor-specific antigen P91A. The single amino acid substitution in P91A results in the expression of a new MHC class I (H-2L(d))-binding peptide. In transgenic tissue, the H-2L(d)/P91A complex is expressed in isolation from other tumor-associated antigens, allowing definition of the immune response to a single defined tumor antigen, a situation closely analogous to events during tumorigenesis. We show that CD8+ T cell immune surveillance of P91A is ineffective without the introduction of a helper determinant operating through stimulation of CD4+ T cells. Recognition of the isolated P91A tumor antigen on normal tissue by CD8+ T cells is a tolerogenic process. Induction of T cell tolerance suggests tumor antigen-T cell interactions occurring during tumorigenesis may elicit T cell tolerance and hence confound some immunotherapeutic approaches.

AB - Much has been learned in recent years concerning the nature of tumor antigens recognized by T cells. To apply this knowledge clinically, the nature of the host response to individual and multiple tumor antigens has to be characterized. This will help to define the efficacy of immune surveillance and the immune status of the host following exposure to tumor antigens expressed on pre-neoplastic tissue. To approach these questions, we have developed a transgenic mouse which expresses the tumor-specific antigen P91A. The single amino acid substitution in P91A results in the expression of a new MHC class I (H-2L(d))-binding peptide. In transgenic tissue, the H-2L(d)/P91A complex is expressed in isolation from other tumor-associated antigens, allowing definition of the immune response to a single defined tumor antigen, a situation closely analogous to events during tumorigenesis. We show that CD8+ T cell immune surveillance of P91A is ineffective without the introduction of a helper determinant operating through stimulation of CD4+ T cells. Recognition of the isolated P91A tumor antigen on normal tissue by CD8+ T cells is a tolerogenic process. Induction of T cell tolerance suggests tumor antigen-T cell interactions occurring during tumorigenesis may elicit T cell tolerance and hence confound some immunotherapeutic approaches.

KW - H-Y

KW - Tolerance

KW - Transgene

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=0030012409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030012409&partnerID=8YFLogxK

U2 - 10.1002/eji.1830260521

DO - 10.1002/eji.1830260521

M3 - Article

VL - 26

SP - 1094

EP - 1102

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 5

ER -